Literature DB >> 14517495

Plasmatic coagulation and fibrinolytic system alterations in PNH: relation to clone size.

Martin Grünewald1, Annelie Siegemund, Anja Grünewald, Anke Schmid, Mario Koksch, Christine Schöpflin, Stefanie Schauer, Martin Griesshammer.   

Abstract

Paroxysmal nocturnal haemoglobinuria (PNH) is characterized pathophysiologically by intravascular lysis of blood cells and clinically by thromboembolic events, often atypical in localization. In this study, we examined the plasmatic coagulation system of PNH patients to investigate a potential relation between coagulation alterations and disease intensity (PNH clone size). We found evidence for both an increase in procoagulant and in fibrinolytic activity, resulting in increased fibrin generation and turnover. Whereas a positive association of the procoagulant potential with PNH clone size was notable, fibrinolytic activity showed an inverse association with clone size. As a possible cause, a growing impairment of fibrinolytic activation and/or an increasing displacement of fibrinolytic activity is assumed. These mechanisms are most likely caused by the detachment of the glycosyl-phosphatidyl-inositol-anchored urokinase plasminogen activator receptor from cell surfaces, causing a progressive resistance to fibrinolytic stimuli, together with a probable shift of the fibrinolytic potential from cell surfaces to soluble, circulating complexes, resulting in a cellular fibrinolysis-steal phenomenon. Together, these processes are accused of mediating an increased thrombophilic risk in PNH. As hereditary prothrombogenic defects were found more frequently in patients suffering ischaemic complications, genetic thrombophilia seems to confer an additional thromboembolic risk in PNH, and should therefore be screened for.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14517495     DOI: 10.1097/00001721-200310000-00011

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  6 in total

1.  Long-term outcome of fludarabine-based reduced-intensity allogeneic hematopoietic cell transplantation for debilitating paroxysmal nocturnal hemoglobinuria.

Authors:  Jeremy Pantin; Xin Tian; Nancy Geller; Catalina Ramos; Lisa Cook; Elena Cho; Phillip Scheinberg; Sumithira Vasu; Hahn Khuu; David Stroncek; John Barrett; Neal S Young; Theresa Donohue; Richard W Childs
Journal:  Biol Blood Marrow Transplant       Date:  2014-05-17       Impact factor: 5.742

2.  Loss of expression of neutrophil proteinase-3: a factor contributing to thrombotic risk in paroxysmal nocturnal hemoglobinuria.

Authors:  Anna M Jankowska; Hadrian Szpurka; Mark Calabro; Sanjay Mohan; Andrew E Schade; Michael Clemente; Roy L Silverstein; Jaroslaw P Maciejewski
Journal:  Haematologica       Date:  2011-05-05       Impact factor: 9.941

3.  Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients.

Authors:  Elaine M Sloand; Loretta Pfannes; Phillip Scheinberg; Kenneth More; Colin O Wu; McDonald Horne; Neal S Young
Journal:  Exp Hematol       Date:  2008-10-26       Impact factor: 3.084

4.  Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab.

Authors:  Dominique Helley; Régis Peffault de Latour; Raphaël Porcher; Celso Arrais Rodrigues; Isabelle Galy-Fauroux; Jeanne Matheron; Arnaud Duval; Jean-François Schved; Anne-Marie Fischer; Gérard Socié
Journal:  Haematologica       Date:  2010-01-15       Impact factor: 9.941

Review 5.  Advances in the diagnosis and therapy of paroxysmal nocturnal hemoglobinuria.

Authors:  Robert A Brodsky
Journal:  Blood Rev       Date:  2007-12-03       Impact factor: 8.250

Review 6.  The central role of extracellular vesicles in the mechanisms of thrombosis in paroxysmal nocturnal haemoglobinuria: a review.

Authors:  Bérangère Devalet; François Mullier; Bernard Chatelain; Jean-Michel Dogné; Christian Chatelain
Journal:  J Extracell Vesicles       Date:  2014-03-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.